Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;18(4):190.
doi: 10.1038/s41585-021-00449-1.

Benefit of nectin-4 targeting with enfortumab vedotin confirmed

Diana Romero  1
Affiliations
Comment

Benefit of nectin-4 targeting with enfortumab vedotin confirmed

Diana Romero. Nat Rev Urol. 2021 Apr.
No abstract available

PubMed Disclaimer

Comment on

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Powles T, et al. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. N Engl J Med. 2021. PMID: 33577729 Free PMC article. Clinical Trial.

References

Original article
    1. Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2035807 (2021) - DOI - PubMed
Related article
    1. Heath, E. I. & Rosenberg, J. E. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat. Rev. Urol. 18, 93–103 (2021) - DOI

LinkOut - more resources